Real‐world effectiveness of adjuvant octreotide therapy in patients with pancreatic neuroendocrine tumors at high recurrence risk: A multicenter retrospective cohort study

奥曲肽 医学 倾向得分匹配 内科学 神经内分泌肿瘤 辅助治疗 胃肠病学 子群分析 回顾性队列研究 肿瘤科 癌症 生长抑素 置信区间
作者
Shiwei Guo,Heshui Wu,Suizhi Gao,Weiyu Hu,Hui Jiang,Yun Bian,Yijie Zhang,Bo Li,Gang� Li,Xuefeng Xu,Min Wang,Chenglin Zhu,Linlin Qu,Qiang Huang,Renyi Qin,Wenhui Lou,Gang Jin
出处
期刊:Journal of Neuroendocrinology [Wiley]
卷期号:36 (12): e13442-e13442 被引量:6
标识
DOI:10.1111/jne.13442
摘要

Adjuvant therapy for pancreatic neuroendocrine tumors (PanNETs) after radical resection lacks evidence-based data and remains controversial. This study aimed to validate whether long-acting octreotide is a potential candidate for adjuvant therapy in patients with G2 PanNETs at high recurrence risk by clustering real-world data. A retrospective review of patients with nonmetastatic grade 2 PanNETs who underwent radical resection at six research centers between 2008 and 2020 was conducted. Propensity score matching and inverse probability of treatment weight analysis were used to control confounding factors. Overall, 357 patients (octreotide group, n = 82; control group, n = 275) were analyzed. Kaplan-Meier survival analyses showed that the octreotide group had longer disease-free survival (DFS) compared with the control group (36 months: 93.3% vs. 79.0%, p = .0124; 60 months: 71% vs. 67.6%, p = .0596, respectively), as well as overall survival (OS) (60 months: 98% vs. 83.8%, p = .0117, respectively). Multivariate analyses indicated that octreotide long-acting repeatable (LAR) adjuvant therapy was associated with higher OS (p = .0270) at 60 months. Propensity score matching analysis showed that octreotide adjuvant therapy was associated with higher DFS (p = .0455) and OS (p = .0190) at 60 months. Similar results were obtained via inverse probability of treatment weight analysis. Subgroup analysis indicated that octreotide LAR was associated with a high DFS in patients with lymph node metastasis or Ki-67 <10% PanNETs. Adjuvant therapy with long-acting octreotide following radical resection of nonmetastatic G2 PanNETs may be associated with improved DFS and OS in a real-world setting.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Wynne_Wang发布了新的文献求助10
刚刚
Mishaoc完成签到,获得积分10
刚刚
1秒前
1秒前
591发布了新的文献求助10
1秒前
wang完成签到,获得积分10
1秒前
博士僧发布了新的文献求助10
1秒前
Fang发布了新的文献求助10
2秒前
小剧场发布了新的文献求助10
2秒前
李sir完成签到,获得积分20
4秒前
躺平的搬砖人完成签到,获得积分10
4秒前
4秒前
4秒前
4秒前
Akim的应助被单纯易真采纳,获得10
5秒前
积极慕晴完成签到,获得积分10
6秒前
科研通AI6.3的应助被不灵0采纳,获得10
6秒前
payload发布了新的文献求助30
6秒前
我是谁的应助被丰富彤采纳,获得30
7秒前
冰块完成签到 ,获得积分10
7秒前
呆萌水风完成签到 ,获得积分10
7秒前
8秒前
丽达完成签到,获得积分10
8秒前
小二郎的应助被Haha采纳,获得10
9秒前
CipherSage的应助被AA采纳,获得10
10秒前
10秒前
英俊的铭的应助被elisa828采纳,获得10
10秒前
口味虾发布了新的文献求助10
10秒前
古娜拉完成签到,获得积分10
10秒前
斯文败类的应助被Log采纳,获得10
11秒前
111完成签到,获得积分10
12秒前
cxt1346完成签到 ,获得积分10
12秒前
香蕉觅云的应助被何88888888采纳,获得10
12秒前
13秒前
Aeon的应助被霍则风采纳,获得50
14秒前
传奇3的应助被WYL采纳,获得10
15秒前
111发布了新的文献求助10
15秒前
桐桐的应助被Atwish采纳,获得10
16秒前
科研通AI6.2的应助被Axle采纳,获得10
17秒前
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190724
求助须知:如何正确求助?哪些是违规求助? 9577784
关于积分的说明 21855018
捐赠科研通 7789883
什么是DOI,文献DOI怎么找? 3436455
关于科研通互助平台的介绍 2560308
邀请新用户注册赠送积分活动 2483172